-
Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
-
Ultimovacs ASA: New share capital registered
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent
-
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
-
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
-
Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma
